Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BSA204 in Chinese Adults With Borderline Elevated Lipoprotein(a)
NCT07551505Phase 1Active, not recruiting
- Sponsor
- BiSiRNA Therapeutics
- Start
- Apr 2026
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BSA204 in dyslipidemia (5 cohorts), sponsored by BiSiRNA Therapeutics. Primary endpoint: Incidence and Severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) at 180 days. Started Apr 2026; status: active, not recruiting.
02
Drugs
BSA204
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT07551505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07551505.